Evidence review demonstrates reduced HIV acquisition risk in high-risk adults, indicating protection depends heavily on medication adherence.
In adults at increased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associated with decreased risk of acquiring HIV infection compared with placebo or no PrEP, although effectiveness decreased with suboptimal adherence.
No takes yet. Share an insight, caveat, or question.
Chou et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: